RxDoctor Payments Data

Jaymi Therese Cheng, MD

General Practice · Batavia, NYNPI 1982958252

Payments from drug & device makers

$1,332in general payments, 2019–2025

Across 13 payments — averaging $102.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mimedx Group, Inc.$1K
  • Urgo Medical North America, LLC$125
  • Lilly USA, LLC$64
  • E.r. Squibb & Sons, L.L.C.$29
  • Amgen$22
  • Novo Nordisk$22
  • plus $13 from 1 others

What the payments were for

  • Travel & lodging$74956%
  • Food & beverage$58344%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,332 in reported general payments places this provider in the 85th percentile of 5,764 general practice providers in New York.

See all general practice providers in New York

Medicare billing

Part B allowed, 2024
$442,345
Medicare patients
345
Services billed
2,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide28$33,966
JanuviaSitagliptin Phosphate27$23,088
JardianceEmpagliflozin19$22,003
EliquisApixaban11$16,258
FarxigaDapagliflozin Propanediol17$12,928
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog18$8,207
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,672
Diflorasone Diacetate12$4,912
Clobetasol Propionate13$3,001
Albuterol Sulfate HfaAlbuterol Sulfate53$2,135
Lidocaine21$2,099
Lantus SolostarInsulin Glargine,hum.Rec.Anlog11$1,527
Labetalol Hcl24$1,354
Atorvastatin Calcium154$1,352
Nifedipine ErNifedipine53$1,186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$22$33,96628 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,764 general practice providers in New York.

Other general practice in Batavia

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →